ABT-333

ABT-333 is a nonnucleoside NS5B polymerase inhibitor for the treatment of HCV infection. An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside polymerase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot study involving patients with HCV genotype 1 infection. ABT-333 is currently under clinical trials for the treatment of Hepatitis C.